All In MedTech

Device Trial Radar · NCT07500246

Advancing Diagnosis and Treatment of Pediatric Asthma

Advancing Diagnosis and Treatment of Pediatric Asthma by Deep Immunophenotyping and Evaluation of Two Spacer Devices for Inhaled Corticosteroid Administration

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 208 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

208

Planned (sponsor's estimate)

Start

Jan 2, 2026

Primary completion

Aug 2027

Study completion Aug 2027

Sponsor

Lead sponsor
Luxembourg Institute of HealthGovernment (non-federal)
Sponsor type
Government (non-federal)
Collaborators
Luxembourg National Research Fund; Centre Hospitalier du Luxembourg; Meracle Health (Luxembourg) S.à.r.l
First posted
Mar 30, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 5 years, up to 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Asthma is one of the most common chronic diseases in children, and treatment success often depends on proper inhaler use and consistent medication adherence. Exposure to allergens and pollutants can also impact treatment response and asthma control. Moreover, there is a growing need for non-invasive biomarkers to support better diagnosis and personalized care. The goal of this clinical trial is to investigate if a new digital inhaler can improve inhalation technique and treatment adherence in children aged 5 to 16 years old, with partly controlled or uncontrolled asthma requiring treatment with inhaled corticosteroids. The main questions it aims to answer are: * Does the use of a digital inhaler improve adherence to inhaled corticosteroids and asthma control in children? * Which biomarkers could support diagnosis and help predict treatment responses in children with asthma? * How do environmental factors influence asthma control and treatment outcomes? Researchers will compare adherence to inhaled corticosteroid therapy between children using a new digital inhaler (Whizz spacer) and those using a standard, non-digital inhaler (AeroChamber Plus® Flow-Vu®) to see if the digital inhaler improves treatment administration and asthma control. They will quantify inflammatory markers in biological samples from asthmatic children and children without respiratory disease, to find biomarkers linked to disease and treatment response. Participants will: * Use the Whizz spacer or the AeroChamber Plus® Flow-Vu® during 12 weeks for corticosteroid inhalation, and complete daily a study diary to follow treatment administration. * Complete asthma control and quality of life questionnaires and have an evaluation of asthma control through GINA score at baseline, 6 and 12 weeks. * Undergo spirometry tests and FENO measurements at baseline and 12 weeks. * Give biological samples at baseline and 12 weeks. * Collect children's bedroom dust samples at baseline. * Wear a bracelet for 7 days at baseline and 12 weeks to monitor physical activity.

Conditions

  • Asthma Childhood
  • Asthma
  • Inhalation Spacers

Interventions

  • Whizz spacer systemDevice

    Whizz spacer is a new digital valved holding chamber that is intended to administer aerosolized medication from the metered dose inhaler to the patient. It allows monitoring of treatment administration through light indicators and a mobile application.

  • AeroChamber Plus® Flow-Vu®Device

    AeroChamber Plus® Flow-Vu® is a standard valved holding chamber used to administer aerosolized medication from the metered dose inhaler to the patient.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Measurement of inhaled corticosteroid therapy adherence and comparison between the two spacersTime frame: From enrolment to the end of the intervention at 12 weeks

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • CHC Mont Légia

    Liège, Belgium · Recruiting

  • Luxembourg Research Clinic (LRC)

    Luxembourg, Luxembourg · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.